



OPEN ACCESS

EDITED AND REVIEWED BY
Robert Gniadecki,
University of Alberta, Canada

*CORRESPONDENCE
P. Régine Mydlarski
✉ rmydlars@ucalgary.ca

RECEIVED 27 May 2024
ACCEPTED 18 June 2024
PUBLISHED 27 June 2024

CITATION
Ma B, Park Y-J, Barber K and Mydlarski PR
(2024) Corrigendum: Nocebo effects in
systemic therapies for adult plaque psoriasis: a
systematic review and meta-analysis.
Front. Med. 11:1439345.
doi: 10.3389/fmed.2024.1439345

COPYRIGHT
© 2024 Ma, Park, Barber and Mydlarski. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: Nocebo effects in systemic therapies for adult plaque psoriasis: a systematic review and meta-analysis

Bryan Ma¹, Ye-Jean Park^{1,2}, Kirk Barber¹ and
P. Régine Mydlarski^{1*}

¹Division of Dermatology, Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada

KEYWORDS

psoriasis, systemic therapy, nocebo effect, randomized controlled trial, biologic

A corrigendum on

Nocebo effects in systemic therapies for adult plaque psoriasis: a systematic review and meta-analysis

by Ma, B., Park, Y.-J., Barber, K., and Mydlarski, P. R. (2024). *Front. Med.* 11:1373520.
doi: 10.3389/fmed.2024.1373520

In the published article, there was an error in Table 1 as published. In the row “Any AE” under the columns “Non-biologic” and “Non-biologic Placebo,” the numbers entered of 57.10 (54.66 – 59.52) and 49.78 (47.12 – 52.44), respectively, are an accidental transposition of these same numbers from the “Intervention Pooled” and “Placebo Pooled” columns. Instead, the numbers under row “Any AE” for column “Non-biologic” should be 63.02 (56.80 – 69.03) and for column “Non-biologic Placebo” should be 48.75 (41.02 – 56.51). The corrected Table 1 appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 Pooled proportion of patients experiencing adverse events and risk difference between systemic therapy and placebo stratified by treatment class.

	Proportion % (95% CI)						Risk difference % (95% CI)		
	Intervention pooled	Placebo pooled	Biologic	Biologic placebo	Non-biologic	Non-biologic placebo	Biologic	Non-biologic	Pooled overall
Any AE	57.10 (54.66 – 59.52)	49.78 (47.12 – 52.44)	55.65 (53.14 – 58.15)	49.92 (47.16 – 52.69)	63.02 (56.80 – 69.03)	48.75 (41.02 – 56.51)	5.26 (3.03 – 7.50)	12.64 (7.29 – 17.99)	6.73 (4.58 – 8.87)
Serious AE	1.79 (1.59 – 2.00)	1.42 (1.15 – 1.71)	1.82 (1.59 – 2.06)	1.29 (1.02 – 1.58)	1.70 (1.30 – 2.14)	1.87 (1.06 – 2.86)	0.36 (0.06 – 0.67)	−0.09 (−1.0 – 0.84)	0.28 (−0.01 – 0.58)
AE leading to discontinuation	2.17 (1.67 – 2.71)	1.90 (1.50 – 2.34)	1.40 (1.11 – 1.70)	1.49 (1.11 – 1.92)	6.47 (4.08 – 9.33)	3.61 (2.67 – 4.68)	0.12 (−0.17 – 0.40)	2.85 (0.53 – 5.17)	0.22 (0.53 – 5.17)
Infectious AE	20.27 (17.63 – 23.04)	15.57 (13.61 – 17.64)	20.09 (17.23 – 23.10)	15.56 (13.46 – 17.78)	21.51 (15.24 – 28.52)	15.69 (10.28 – 21.94)	4.31 (2.83 – 5.79)	4.14 (1.50 – 6.78)	4.34 (2.99 – 5.69)
Injection- or Infusion-related AE	NA	NA	4.92 (3.39 – 6.69)	1.69 (1.00 – 2.50)	NA	NA	3.40 (1.91 – 4.89)	NA	NA

AE, adverse event; CI, confidence interval; NA, not applicable.

Bolded values are significantly different from 0 testing at a significance level of 5%.